Summary

Because Tumor necrosis factor inhibitors (TNFis) are expensive, however, there is currently much interest in lower-cost biosimilars—biological products that are highly similar to a licensed reference biological product with no clinically meaningful differences in safety, potency, and purity. This article presents results of a phase 3, randomized, double-blind, active comparator trial of the biosimilar BOW015 to its reference drug infliximab in patients with active rheumatoid arthritis.